Paris, 12th November 2018: In an all-time record year for FDA approvals (48 so far in 2018), Pharmapack Europe reports that innovation is also … Keep Reading
[column]The U.S. Food and Drug Administration has approved Pomalyst (pomalidomide) to treat patients with multiple myeloma whose disease progressed after being treated with other cancer drugs. Multiple myeloma is a form of blood cancer that primarily affects older adults and arises from plasma cells in the bone marrow.
[column]The U.S. Food and Drug Administration has approved a new use of Gleevec (imatinib) to treat children newly diagnosed with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL). ALL is the most common type of pediatric cancer, affecting approximately 2,900 children annually,
An exclusive pharmacy poem was added to make you laugh. Have knowledge, Have fun!